PHOTODYNAMIC THERAPY (PDT):
ADVANCED OPTIONS & GLOBAL ACCESS

PDT is built on a photochemical reaction requiring three elements simultaneously: a photosensitiser, light of a specific wavelength, and molecular oxygen. Remove any one — no treatment effect.

“PDT is uniquely selective: it destroys cancer where the photosensitiser accumulates and light is delivered — leaving surrounding normal tissue largely unaffected.”

• The Photosensitiser

  A light-absorbing chemical that accumulates preferentially in tumour tissue. Administered intravenously (systemic PDT) or topically (skin PDT). Remains inactive until exposed to light of the correct wavelength matched to its absorption peak.

• The Light

  Monochromatic laser or LED light at a wavelength matching the photosensitiser's peak absorption. Delivered via surface illumination (skin), endoscope-coupled optical fibre (internal tumours), or interstitial needle fibres (solid tumours). Light does not reach distant sites — PDT is inherently local.

• The Oxygen

  Molecular oxygen dissolved in tumour tissue is converted by the photosensitiser's triplet excited state to singlet oxygen (¹O₂) — the primary cytotoxic mediator. Singlet oxygen has a lifetime of microseconds and a diffusion radius of ~20nm — ensuring highly localised damage at the site of photosensitiser activation.

• Three Mechanisms of Tumour Destruction

  PDT kills tumours simultaneously through: (1) direct cancer cell death via singlet oxygen-mediated apoptosis and necrosis; (2) vascular shutdown — photodynamic damage to tumour blood vessels causing infarction; and (3) immune activation — immunogenic cell death releasing DAMPs that prime anti-tumour immunity.

The choice of photosensitiser determines the activation wavelength, tissue penetration depth, drug-to-light interval, photosensitivity duration, and tumour selectivity. Understanding which agent will be used — and its properties — is an important patient question.

PDT has 30+ years of clinical evaluation resulting in regulatory approvals across multiple jurisdictions. The table below distinguishes curative-intent from palliative applications — an important distinction patients should clarify with their treating centre.

PDT has distinct advantages in specific clinical niches — driven by its tissue selectivity, functional preservation, and ability to treat lesions accessible by endoscope or surface light. These are the four most clinically significant applications.

• Oesophageal Cancer: Curative and Palliative

  For mucosal early-stage SCC (T1a/T1b SM1), PDT achieves CR rates of 70–90% at Japanese and Chinese expert centres — an organ-preserving alternative to surgery. For advanced obstructing disease, PDT restores swallowing (dysphagia palliation) with superiority to Nd:YAG laser in the only RCT.

• Lung Cancer: Airway Preservation

  In situ or microinvasive central airway SCC in patients unfit for surgery: PDT achieves CR in 70–90% and preserves lung function entirely. For obstructing central airway tumours, PDT recanalises the airway, relieves breathlessness, and reduces post-obstructive pneumonia — critical palliation in advanced disease.

• Skin Cancer: Cosmesis and Field Treatment

  ALA/MAL-PDT is uniquely suited for actinic keratosis 'field cancerisation' — treating an entire sun-damaged area rather than individual lesions. For superficial BCC in cosmetically sensitive areas (face, nose, scalp), PDT achieves CR with excellent cosmetic outcome — superior to excision or cryotherapy for appearance.

• NPC Recurrence: China's Unique Expertise

  Locally recurrent NPC after radiotherapy — where re-irradiation risks severe toxicity — is uniquely served by PDT at Chinese expert centres. Sun Yat-sen University Cancer Centre in Guangzhou achieves CR rates of 60–80% for superficial NPC recurrence using endoscopic nasopharyngeal PDT — an indication with no equivalent Western programme.

Understanding the PDT process end-to-end — from photosensitiser administration to post-procedure precautions — reduces anxiety and ensures patients are fully prepared for the most critical aspect of safe PDT: photosensitivity management.

1. 1

   Pre-Treatment Assessment

   Biopsy-confirmed diagnosis, endoscopic or imaging characterisation of tumour depth, performance status, and organ function review. Photosensitising medications reviewed. Baseline imaging for staging. Informed consent including photosensitivity precautions discussed in detail.

2. 2

   Photosensitiser Administration

   Intravenous infusion of photosensitiser (Photofrin: 2mg/kg; Photochlor; Temoporfin). Drug accumulates preferentially in tumour tissue over 24–96 hours. Patient begins photosensitivity precautions immediately — avoiding direct sunlight, bright indoor lights, and windows in direct sun.

3. 3

   Light Delivery Procedure

   Performed under conscious sedation or general anaesthesia depending on site. For internal tumours: endoscope-guided optical fibre delivers laser light (630–664nm) for 8–16 minutes. For skin: surface LED or laser illumination. Light dose precisely calculated (J/cm or J/cm²). Total procedure time 15–60 minutes.

4. 4

   Immediate Post-Treatment Reaction (Days 1–7)

   Tumour swelling, inflammation, and necrosis at the treated site. For endobronchial PDT: bronchoscopic debridement at 48–72 hours to clear necrotic tumour plug and prevent airway obstruction — standard at expert centres. For oesophageal PDT: transient dysphagia worsening from oedema, resolving in 1–2 weeks.

5. 5

   Photosensitivity Precautions (Weeks 1–6)

   The most important post-treatment requirement. Cover all exposed skin (long sleeves, gloves, hat, UV-opaque mask) whenever outdoors. Avoid windows in direct sunlight indoors. Avoid powerful spotlights and halogen lamps. Test skin sensitivity progressively after the sensitiser-specific clearance period before returning to normal activity.

6. 6

   Response Assessment (Week 4–8)

   Endoscopy (oesophageal, endobronchial, bladder), CT, or PET-CT at 4–8 weeks post-PDT to assess treatment response. CR = no residual tumour. PR = residual tumour amenable to repeat PDT or alternative treatment. Response guides decision on further sessions or adjuvant therapy.

PDT's side effects are fundamentally different from chemotherapy or radiation — they are primarily local (at the treated site) and photosensitivity-related (sun exposure). Understanding both categories ensures safe management.

PDT-induced immunogenic cell death primes the immune system against tumour antigens — creating a scientifically compelling rationale for combining PDT with checkpoint inhibitors. China's oncology trial network is the most active globally in this combination.

• Why PDT Makes Immunotherapy Work Better

  PDT-induced cell death releases DAMPs — HMGB1, calreticulin, heat shock proteins, ATP — that activate dendritic cells and initiate anti-tumour T-cell responses. PDT also disrupts the immunosuppressive tumour microenvironment, temporarily overcoming one of the key mechanisms of checkpoint inhibitor resistance.

• China's PDT + PD-1 Clinical Trial Programme

  Chinese Phase I/II trials combine PDT with sintilimab, camrelizumab, and tislelizumab for oesophageal cancer, NPC, lung cancer, and HCC — indications where both PDT and PD-1 inhibitors have independent activity. Early data show improved response rates and durability compared to either modality alone.

• PDT + Chemotherapy and Radiation

  PDT combined with concurrent or sequential chemotherapy addresses micrometastatic disease while PDT controls the primary tumour. Chinese clinical series in oesophageal cancer show superior local control for PDT + chemotherapy vs chemotherapy alone. PDT as a radiation sensitiser is under investigation for locally advanced head and neck tumours.

China has one of the world's most active clinical PDT programmes. India's programme is smaller but has important strengths for oesophageal, head and neck, and skin cancer. Both offer PDT at dramatically lower cost than Western centres.

• CAMS Cancer Hospital Beijing

  China's national cancer institute and the reference PDT centre — with programmes in oesophageal, lung, and bladder cancer using both Photofrin and domestically produced Photochlor/DVDMS. Primary centre for CancerFax referrals for non-NPC indications.

• Sun Yat-sen University Cancer Centre (Guangzhou)

  China's premier NPC centre and the only high-volume programme for PDT of recurrent NPC — achieving CR rates of 60–80% for superficial recurrence after radiotherapy. Specialist NPC-PDT expertise unmatched globally.

• Henan Cancer Hospital (Zhengzhou)

  High-volume oesophageal cancer PDT centre in Henan province — one of China's highest oesophageal cancer incidence regions. Extensive series of early-stage oesophageal SCC treated with curative-intent PDT. Practical access point for South Asian patients travelling to China.

• Tata Memorial Centre (Mumbai)

  India's most experienced PDT centre — oesophageal, head and neck, and skin cancer PDT using Photofrin for internal tumours and ALA/MAL for dermatological indications. Oral cancer and leucoplakia PDT is a specific strength, particularly relevant for India's high oral cancer burden.

Data from landmark trials and published clinical series defining PDT's efficacy across its principal indications.

• 70–90%CR Rate — Early Oesophageal / Endobronchial SCCComplete response rate for in situ or mucosal early-stage SCC at expert Japanese and Chinese PDT centres.
• 493 daysMedian OS — Cholangiocarcinoma + PDTOrtner 2003 RCT: PDT + biliary stenting vs stenting alone. PDT arm: 493 days median OS vs 98 days — a 5× survival benefit.
• 60–80%CR Rate — Recurrent NPC (Sun Yat-sen)For superficial NPC recurrence after radiotherapy, treated with endoscopic PDT at Sun Yat-sen University Cancer Centre.
• 4–6 weeksPhotofrin Photosensitivity DurationThe main quality-of-life limitation of 1st-generation PDT. Talaporfin (Japan) and ALA (topical) reduce this to 24–48 hours.
• 92–95%CR Rate — Early Central Lung CancerJapanese talaporfin and NPe6-based PDT series reported very high complete response rates in centrally located early lung cancer, especially for small superficial lesions.
• 76%5-Year OS — Salvage PDT for Local Esophageal FailureIn Japanese salvage-PDT data for local failure after chemoradiotherapy, 5-year overall survival reached 76%, showing that PDT can be a meaningful organ-preserving option in selected patients.

Post-PDT monitoring follows a structured timeline. The timing of response assessment varies by cancer type and delivery route — patients should confirm the follow-up plan with their treating centre before discharge.

1. 1

   48–72 Hours: Bronchoscopic Debridement (Endobronchial PDT)

   Mandatory for endobronchial PDT — removal of necrotic tumour plug to prevent airway obstruction. Performed under bronchoscopy at the treating centre. Fever from necrosis absorption managed with antipyretics.

2. 2

   Week 1–2: Local Reaction Management

   Assessment of oedema, pain, and local tissue reaction at treated site. For oesophageal PDT: confirm swallowing improving. For skin PDT: wound care and sun protection advice. Contact treating team if reactions seem unexpectedly severe.

3. 3

   Week 4–8: Primary Response Assessment

   Endoscopy (oesophageal, endobronchial, bladder) or CT/PET-CT (solid tumours, bile duct) to assess CR vs PR vs non-response. CR confirms treatment success. PR identifies residual tumour — repeat PDT or alternative treatment decision.

4. 4

   If PR or Residual Disease: Repeat PDT Decision

   A second PDT session can be performed at the same or adjacent site. Most centres recommend reassessment at 4–8 weeks and re-illumination if residual tumour is present without evidence of submucosal invasion (which would preclude curative intent).

5. 5

   Ongoing Surveillance: 3–6 Monthly

   After confirmed CR: endoscopic or imaging surveillance every 3–6 months for the first 2 years, then annually. Early detection of recurrence allows repeat PDT or alternative treatment before the cancer becomes more advanced.

Costs include photosensitiser drug, light delivery procedure, endoscopy/bronchoscopy for internal tumours, anaesthesia, hospital stay, and bronchoscopic debridement where applicable. Photosensitiser cost is the largest single cost variable.

Each short-form guide addresses a specific PDT question in plain language, from photosensitizer choice to managing photosensitivity.

Frequently Asked Questions